公开(公告)号：US20240226121A1

公开(公告)日：2024-07-11

申请号：US18433084

申请日：2024-02-05

Applicant: Pedro P. Perez

Inventor： Pedro P. Perez

IPC: A61K31/00 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K9/48 ,  A61K47/12 ,  A61K47/22 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44 ,  A61K47/46

CPC classification number: A61K31/658 ,  A61K9/0095 ,  A61K9/06 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2068 ,  A61K9/4858 ,  A61K9/4875 ,  A61K47/12 ,  A61K47/22 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44 ,  A61K47/46

Abstract: A phytocannabinoid formulation comprises an amount of at least about 90 percent by weight of one or more phytocannabinoid. The phytocannabinoid formulation further comprises an amount of at least about 0.1 percent by weight of a plurality of lipophilic molecules including at least one saturated straight chain C14-C20 fatty acid and at least one unsaturated ω-6 C18-C22 fatty acid. The phytocannabinoid formulation also includes an amount of at least about 0.1 percent by weight of at least one bioflavonoid.

公开(公告)号：US20240130985A1

公开(公告)日：2024-04-25

申请号：US18047960

申请日：2022-10-18

Applicant: Genexa Inc.

Inventor： Max Spielberg ,  David Johnson

IPC: A61K31/167 ,  A61K9/20

CPC classification number: A61K31/167 ,  A61K9/2013 ,  A61K9/2068

Abstract: A tablet includes an active material and a base material that carnauba wax and an oil.

公开(公告)号：US11890381B2

公开(公告)日：2024-02-06

申请号：US17468717

申请日：2021-09-08

Applicant: NITIKA PHARMACEUTICAL SPECIALITIES PVT. LTD.

Inventor： Ravleen Singh Khurana

IPC: A61K9/20

CPC classification number: A61K9/2059 ,  A61K9/2068

Abstract: A present invention relates to a natural lubricant composition, a tablet comprising a natural lubricant composition and a preparation method thereof. The Natural Lubricant composition for a tablet comprises an active lubricant ingredient selected from a corn flour, a corn starch, and an arrowroot flour. The Natural Lubricant composition for a tablet also comprises a natural oil.

公开(公告)号：US11826459B2

公开(公告)日：2023-11-28

申请号：US17248968

申请日：2021-02-16

Applicant: AMERILAB TECHNOLOGIES, INC.

Inventor： Carrie Kraling ,  Sarah Olson ,  Shayna Jilek

IPC: A61K9/46 ,  A61K9/20 ,  A61K9/16 ,  A61K9/00 ,  C13B50/00 ,  C13B50/02

CPC classification number: A61K9/0007 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/1623 ,  A61K9/1664 ,  A61K9/205 ,  A61K9/2018 ,  A61K9/2068 ,  C13B50/002 ,  C13B50/02

Abstract: An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and optionally a lubricant derived from rice hulls (e.g., a multi-component integral lubricant).

公开(公告)号：US11730709B2

公开(公告)日：2023-08-22

申请号：US17113476

申请日：2020-12-07

Applicant: Infirst Healthcare Limited

Inventor： Robin M. Bannister ,  John Brew

IPC: A61K31/192 ,  A61K47/10 ,  A61K47/14 ,  A61K9/06 ,  A61K9/08 ,  A61K47/44 ,  A61K9/20 ,  A61K31/196 ,  A61K9/48 ,  A61K31/436 ,  A61K31/194 ,  A61K31/381 ,  A61K31/4035 ,  A61K31/421 ,  A61K31/423 ,  A61F5/02 ,  A63B23/02 ,  A61K31/60 ,  A61K9/00 ,  A61K31/19

CPC classification number: A61K31/192 ,  A61F5/026 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/06 ,  A61K9/08 ,  A61K9/2013 ,  A61K9/2068 ,  A61K9/4875 ,  A61K31/194 ,  A61K31/196 ,  A61K31/381 ,  A61K31/4035 ,  A61K31/421 ,  A61K31/423 ,  A61K31/436 ,  A61K31/60 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44 ,  A63B23/02 ,  A61H2201/0192 ,  A61H2201/1614 ,  A61H2201/1652 ,  A61K31/19

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

公开(公告)号：US11642312B2

公开(公告)日：2023-05-09

申请号：US17245414

申请日：2021-04-30

Applicant: MARENDA PHARMACEUTICALS LLC

Inventor： Andrew Favara ,  Marc Karetny

IPC: A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K31/192 ,  A61P29/00 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/44

CPC classification number: A61K9/0056 ,  A61K9/009 ,  A61K9/08 ,  A61K9/2018 ,  A61K9/2068 ,  A61K31/192 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/44 ,  A61P29/00

Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

公开(公告)号：US20180296526A1

公开(公告)日：2018-10-18

申请号：US15766426

申请日：2016-10-07

Applicant: KYOWA HAKKO KIRIN CO., LTD.

Inventor： Shinji TANIMURA ,  Hiroko Yoshii ,  Kenji IWATA ,  Naoto IZAWA ,  Motohiro OTA

IPC: A61K31/402 ,  A61K9/20 ,  A61K9/28

CPC classification number: A61K31/402 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2068 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2886

Abstract: The present invention provides a pharmaceutical composition and the like comprising (4-{(3S)-3-[(1R)-1-(naphthalen-1-yl)ethylamino]pyrrolidin-1-yl}phenyl)acetic acid (Compound A) or a pharmacologically acceptable salt thereof and a diluent.

公开(公告)号：US20180263953A1

公开(公告)日：2018-09-20

申请号：US15923066

申请日：2018-03-16

Applicant: CannTab Therapeutics, Limited

Inventor： Jeff Scott Renwick ,  Robert Lefler

IPC: A61K31/352 ,  A61K9/20 ,  A61K31/05 ,  A61K36/185

CPC classification number: A61K31/352 ,  A61K9/2013 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2068 ,  A61K9/2072 ,  A61K9/2095 ,  A61K31/05 ,  A61K36/185

Abstract: The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. The present invention also provides large scale batches of modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients.

公开(公告)号：US20180243237A1

公开(公告)日：2018-08-30

申请号：US15964635

申请日：2018-04-27

Applicant: Grünenthal Gmbh

Inventor： Elisabeth Arkenau-Maric ,  Johannes Bartholomaus ,  Heinrich Kugelmann

IPC: A61K31/135 ,  A61K45/06 ,  A61K9/20 ,  B29C47/40 ,  B29C47/06 ,  B29C47/00 ,  A61K47/10 ,  A61K36/81 ,  A61K36/67 ,  A61K31/5513 ,  A61K31/515 ,  A61K31/485 ,  A61K31/4725 ,  B29K71/00 ,  B29K105/00 ,  B29L31/00

CPC classification number: A61K31/135 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2068 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/4725 ,  A61K31/485 ,  A61K31/515 ,  A61K31/5513 ,  A61K36/67 ,  A61K36/81 ,  A61K45/06 ,  A61K47/10 ,  B29C48/0011 ,  B29C48/0022 ,  B29C48/022 ,  B29C48/03 ,  B29C48/18 ,  B29C48/40 ,  B29K2071/02 ,  B29K2105/0035 ,  B29K2105/0088 ,  B29K2105/25 ,  B29K2995/007 ,  B29K2995/0089 ,  B29L2031/753 ,  A61K2300/00

Abstract: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.

公开(公告)号：US20180147249A1

公开(公告)日：2018-05-31

申请号：US15825884

申请日：2017-11-29

Applicant: ZHEJIANG STRONG PHARMACEUTICAL CO., LTD.

Inventor： Luping YU

IPC: A61K36/9068 ,  A61K36/9062 ,  A61K36/28 ,  A61K36/708 ,  A61K36/8945 ,  A61K36/9064 ,  A61K36/65 ,  A61K36/539 ,  A61K36/899 ,  A61K9/16

CPC classification number: A61K36/9068 ,  A61K9/0095 ,  A61K9/1652 ,  A61K9/2068 ,  A61K9/4866 ,  A61K36/28 ,  A61K36/539 ,  A61K36/65 ,  A61K36/708 ,  A61K36/8945 ,  A61K36/899 ,  A61K36/9062 ,  A61K36/9064 ,  A61K2236/331 ,  A61K2236/333 ,  A61K2236/37 ,  A61K2236/39 ,  A61K2236/51 ,  A61K2236/53 ,  A61K2300/00

Abstract: A pharmaceutical composition for treating eczema is disclosed. The pharmaceutical composition includes, by weight, 2 to 6 parts of Dried Rhizoma Zingiberis Officinalis, 2 to 6 parts of Paeonia Lactiflora, 1 to 4 parts of Fructus Amomi, 0.5 to 3 parts of Semen Alpiniae Katsumadai, 0.5 to 3 parts of Inula helenium, 0.5 to 3 parts of Radix Et Rhizoma Rhei and 0.5 to 3 parts of Rhizoma Dioscoreae. The components of the pharmaceutical composition synergistically cooperate to clear and disinhibit the liver and gallbladder and clear away damp heat from the body. The pharmaceutical composition can be used to treat skin eczema symptoms caused by metabolic disorders of the liver and gallbladder functions. A method for preparing the pharmaceutical composition is also disclosed.